Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

On-chip activation and subsequent detection of individual antigen-specific T cells.

Song Q, Han Q, Bradshaw EM, Kent SC, Raddassi K, Nilsson B, Nepom GT, Hafler DA, Love JC.

Anal Chem. 2010 Jan 15;82(2):473-7. doi: 10.1021/ac9024363.

2.

Visualizing antigen specific CD4+ T cells using MHC class II tetramers.

James EA, LaFond R, Durinovic-Bello I, Kwok W.

J Vis Exp. 2009 Mar 6;(25). pii: 1167. doi: 10.3791/1167.

3.

Detection of autoreactive CD4 T cells using major histocompatibility complex class II dextramers.

Massilamany C, Upadhyaya B, Gangaplara A, Kuszynski C, Reddy J.

BMC Immunol. 2011 Jul 18;12:40. doi: 10.1186/1471-2172-12-40.

5.
6.

Use of MHC class II tetramers to investigate CD4+ T cell responses: problems and solutions.

Cecconi V, Moro M, Del Mare S, Dellabona P, Casorati G.

Cytometry A. 2008 Nov;73(11):1010-8. doi: 10.1002/cyto.a.20603.

7.

Major Histocompatibility Complex Class II Dextramers: New Tools for the Detection of antigen-Specific, CD4 T Cells in Basic and Clinical Research.

Massilamany C, Krishnan B, Reddy J.

Scand J Immunol. 2015 Nov;82(5):399-408. doi: 10.1111/sji.12344. Review.

8.

MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.

Ilkovitch D, Ostrand-Rosenberg S.

Cancer Immunol Immunother. 2004 Jun;53(6):525-32. Epub 2004 Jan 17.

PMID:
14730400
10.

CD4(+) T cells kill HLA-class-II-antigen-positive melanoma cells presenting peptide in vitro.

Brady MS, Lee F, Petrie H, Eckels DD, Lee JS.

Cancer Immunol Immunother. 2000 Feb;48(11):621-6.

PMID:
10663609
11.

Presentation of arthritogenic peptide to antigen-specific T cells by fibroblast-like synoviocytes.

Tran CN, Davis MJ, Tesmer LA, Endres JL, Motyl CD, Smuda C, Somers EC, Chung KC, Urquhart AG, Lundy SK, Kovats S, Fox DA.

Arthritis Rheum. 2007 May;56(5):1497-506.

12.

Identification of MHC class II restricted T-cell-mediated reactivity against MHC class I binding Mycobacterium tuberculosis peptides.

Wang M, Tang ST, Stryhn A, Justesen S, Larsen MV, Dziegiel MH, Lewinsohn DM, Buus S, Lund O, Claesson MH.

Immunology. 2011 Apr;132(4):482-91. doi: 10.1111/j.1365-2567.2010.03383.x. Epub 2011 Feb 7.

13.
14.

Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers.

Ayyoub M, Dojcinovic D, Pignon P, Raimbaud I, Schmidt J, Luescher I, Valmori D.

Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7437-42. doi: 10.1073/pnas.1001322107. Epub 2010 Apr 5.

15.

MHC class II tetramers containing influenza hemagglutinin and EBV EBNA1 epitopes detect reliably specific CD4(+) T cells in healthy volunteers.

Ye M, Kasey S, Khurana S, Nguyen NT, Schubert S, Nugent CT, Kuus-Reichel K, Hampl J.

Hum Immunol. 2004 May;65(5):507-13.

PMID:
15172451
17.

T cell responses to bluetongue virus are directed against multiple and identical CD4+ and CD8+ T cell epitopes from the VP7 core protein in mouse and sheep.

Rojas JM, Rodríguez-Calvo T, Peña L, Sevilla N.

Vaccine. 2011 Sep 16;29(40):6848-57. doi: 10.1016/j.vaccine.2011.07.061. Epub 2011 Jul 30.

PMID:
21807057
18.
19.

Detection of low-frequency human antigen-specific CD4(+) T cells using MHC class II multimer bead sorting and immunoscope analysis.

Lemaître F, Viguier M, Cho MS, Fourneau JM, Maillère B, Kourilsky P, Van Endert PM, Ferradini L.

Eur J Immunol. 2004 Oct;34(10):2941-9.

20.

Transient T and B cell activation after neonatal induction of tolerance to MHC class II or Mls alloantigens.

Schurmans S, Brighouse G, Kramer G, Wen L, Izui S, Merino J, Lambert PH.

J Immunol. 1991 Apr 1;146(7):2152-60.

PMID:
1672344
Items per page

Supplemental Content

Write to the Help Desk